Jean-Baptiste Lattouf¹, Jenny J. Ko², Margot K. Davis³, Christian Constance⁴, Geoffrey T. Gotto⁵

Canadian Journal of Urology, Vol.31, No.5, pp. 11977-11985, 2024

Abstract Introduction: Niraparib, a PARP1/2 inhibitor, is newly approved in combination with abiraterone acetate (AA) plus prednisone or prednisolone (niraparib/AA+P) for the treatment of adult patients with BRCA-mutated, treatment-naïve metastatic castration resistant prostate cancer (mCRPC). Detailed guidance beyond the prescribing information may be helpful in managing the side effect profile and dosing practicalities of this combination therapy.
Materials and methods: A panel of specialists convened to design management algorithms for four common niraparib/ AA+P treatment-related adverse events (AEs) in mCRPC; anemia, thrombocytopenia, hypertension, and nausea. The algorithms build on Health Canada-approved prescribing information to highlight practical considerations related… More >

Leslie M. Peard¹, Seth Teplitsky¹, Arati Annabathula², William Gunnar³, Peter Mills⁴, Andrew Harris^1,2

Canadian Journal of Urology, Vol.30, No.2, pp. 11467-11472, 2023

Abstract Introduction: Adverse events in urologic procedures are poorly studied. This study analyzes the Veterans Health Administration (VHA) Root Cause Analysis (RCA) data for patient safety adverse events during urologic procedures performed in a VHA operating room (OR).
Materials and methods: The VHA National Center for Patient Safety RCA database was queried for fiscal years 2015-2019 using urologic terms including vasectomy, prostatectomy, nephrectomy, cystectomy, cystoscopy, lithotripsy, ureteroscopy, urethral, TURBT, etc. RCAs for events outside a VHA OR were excluded. Cases were categorized based on type of event.
Results: Sixty-eight RCAs were identified for 319,713 urologic procedures. The most common… More >

David-Dan Nguyen^1,*, Massine Fellouah^2,*, Anna-Lisa V. Nguyen³, David-Christian Kazu⁴, Isabel Baltzan⁵, Muhieddine Labban⁶, Shubha De⁷, Kevin C. Zorn⁸, Bilal Chughtai⁹, Dean S. Elterman¹, Quoc-Dien Trinh⁶, Naeem Bhojani⁸

Canadian Journal of Urology, Vol.30, No.3, pp. 11546-11550, 2023

Abstract Introduction: 5α-reductase inhibitors (5ARI) are commonly prescribed medications. There is ongoing controversy about the adverse events of these medications. The aim of this study is to characterize lawsuits in Canada involving medical complications of 5ARIs use.
Materials and methods: Legal cases were queried from CanLII. Cases were included if they involved a party taking a 5ARI who alleged an adverse event. Relevant full cases were retained, and pertinent characteristics were extracted with the help of a legal expert.
Results: Our deduplicated search yielded 67 unique legal documents from December 2013 to February 2019. Twelve of these documents met… More >

Jacob Wise¹, Raj Tiwari¹, Sophie O'Halloran¹, Lauren Fleshner¹, Susan Nguyen¹, Karen Hersey¹, Nazanin Fallah-Rad², Neil Fleshner¹

Canadian Journal of Urology, Vol.29, No.3, pp. 11136-11141, 2022

Abstract Introduction: Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor used to treat metastatic renal cell carcinoma (mRCC). Patients on sunitinib do require regular in-person appointments to monitor for adverse events (AEs). Given the Covid-19 pandemic, regular in-person visits expose patients to an increased risk of infection in addition to potentially preventable travel costs. This study investigated the feasibility of implementing a remote monitoring strategy for patients being treated with sunitinib for mRCC by examining the time trends of AEs.
Materials and methods: In this retrospective chart review of patients with a diagnosis of mRCC, 167 patients received… More >

Jeffrey Lee, Elie Kaplan-Marans, Dhaval Jivanji, Daniel Tennenbaum, Ariel Schulman

Canadian Journal of Urology, Vol.29, No.6, pp. 11361-11365, 2022

Abstract Introduction: Flexible cystoscopes can be multi-use devices that visually inspect genitourinary structures such as the bladder and urethra. The objective of this study is to characterize the adverse events and associated device malfunctions of reusable flexible cystoscopes and to provide information on contamination and post-procedural infections.
Materials and methods: The Manufacturer and User Facility Device Experience (MAUDE) database was queried for all adverse events and device malfunctions related to the use of flexible cystoscopes between January 2015 and December 2020. The MAUDE adverse event classification system was used to standardize the severity of complications and special focus… More >

XUE MEI LUO¹, SHAHANAVAJ KHAN^2,3,4,*, ABDUL MALIK², FAHAD M. ALDAKHEEL⁵, ANIS AHMAD CHAUDHARY⁶, SHOUKI BAZARBASHI⁷, FATEMEH TABATABAIE⁸

BIOCELL, Vol.46, No.3, pp. 759-767, 2022, DOI:10.32604/biocell.2022.016586 - 18 November 2021

Abstract Despite the multiple systematic reviews and meta-analyses accumulating evidence on the preventive effect of calcium supplementation for colorectal cancer, most of the associated adverse effects are not systematically analyzed. The aim of the study is evaluating adverse events associated with calcium supplementation for colorectal cancer prevention through a systematic meta-analysis. We searched Medline, PubMed Central, EMBASE (Excerpta Medica database), Scopus, Cochrane Central Register of Controlled Trials, and Web of Science published in English from database inception up to 31 July 2019. In the current systematic meta-analysis, we included human studies (including cohort studies, clinical trials,… More >

R. Sujatha¹, B. Venkata Siva Krishna¹, Jyotir Moy Chatterjee², P. Rahul Naidu¹, NZ Jhanjhi^3,*, Challa Charita¹, Eza Nerin Mariya¹, Mohammed Baz⁴

Intelligent Automation & Soft Computing, Vol.32, No.1, pp. 525-541, 2022, DOI:10.32604/iasc.2022.021216 - 26 October 2021

Abstract In the current times, COVID-19 has taken a handful of people’s lives. So, vaccination is crucial for everyone to avoid the spread of the disease. However, not every vaccine will be perfect or will get success for everyone. In the present work, we have analyzed the data from the Vaccine Adverse Event Reporting System and understood that the vaccines given to the people might or might not work considering certain demographic factors like age, gender, and multiple other variables like the state of living, etc. This variable is considered because it explains the unmentioned variables… More >

Yoann Perreux¹, Marie Alexandre Chaix², Anna Kamp³, François-Pierre Mongeon², Magali Pham², Loïc Boussel¹, Roland Henaine¹, Annie Dore², Blandine Mondésert², Sylvie Di-Filippo¹, Paul Khairy², Francis Bessiere^1,*

Congenital Heart Disease, Vol.15, No.6, pp. 473-482, 2020, DOI:10.32604/CHD.2020.013032 - 02 November 2020

Abstract Sudden cardiac death and heart failure are well known long-term complications after atrial switch for D-transposition of the great arteries (D-TGA). Right systemic ventricular dysfunction is common and myocardial ischemia has been implicated as a putative mechanism for sudden death, with coronary anomalies prevalent in 30% of cases. We sought to assess an association between adverse events and coronary anomalies in patients with D-TGA and atrial switch surgery. An observational study was conducted in 3 tertiary centers (Montreal Heart Institute, Canada, Nationwide Children’s hospital, Chicago, USA and Hopital cardiologique Louis Pradel de Lyon, France). Adults… More >

Noriko Ninomiya, Satoshi Tamada, Minoru Kato, Takeshi Yamasaki, Taro Iguchi, Tatsuya Nakatani

Canadian Journal of Urology, Vol.22, No.3, pp. 7798-7804, 2015

Abstract Introduction: We investigated therapeutic outcomes in consecutive patients with metastatic renal cell carcinoma treated with targeted anticancer agents from 2008 to 2014 in order to determine the efficacy of adverse event management for such agents and the best sequence in which to use them.
Materials and methods: We analyzed 132 consecutive patients who had taken targeted anticancer agents for metastatic renal cell carcinoma. Of these, 101 patients received therapy between 2008 and 2011 (pioneer group) and 31 patients received therapy between 2011 and 2014 (contemporary group). Patients of the contemporary group were provided with aggressive adverse… More >

Caroline Jamison^*, Debra Nelson^†, Mete Eren^†, Dron Gauchan^†, Ryan Ramaekers^†, Max Norvell^†, Mehmet Sitki Copur^†

Oncology Research, Vol.23, No.1-2, pp. 1-5, 2015, DOI:10.3727/096504015X14452563485986

Abstract Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg once daily after demonstration of the same efficacy with less toxicity. Some patients require significant dose reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients may require further dose reductions due to substantial toxicity while maintaining good control of their disease. We report two CP-CML patients achieving and maintaining major molecular responses More >